ReviewClinical and experimental medicine2025
CCAT2 role in gastrointestinal cancer progression and metastasis: a novel target for therapeutic strategies.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- MicroRNA expression profiles in abdominal aortic aneurysms: A systematic review of potential diagnostic and prognostic biomarkers.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Long non-coding RNA C20orf56 as a predictor of response to neoadjuvant CCRT and survival rates of rectal cancers.Histology and histopathology · 2026Article
- Harnessing the LncRNA CCAT2 role in gastric cancer: from molecular insights to clinical implications.Cancer cell international · 2026Review
- LncRNA CCAT2 role in female-related cancer progression and diagnosis: a comprehensive review.Clinical and experimental medicine · 2026Review
- The CCAT2 enigma: pioneering insights into colorectal cancer pathophysiology and therapeutic innovation.Cancer cell international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) are a class of non-protein-coding RNAs that have over 200 nucleotides. Various studies have shown that aberrant expression of lncRNAs can lead to the development of different tumors. Furthermore, recent findings revealed that abnormal lncRNA expression can significantly influence cancer-related processes such as proliferation, migration, invasion, metastasis, and epithelial-mesenchymal transition. Colon cancer-associated transcript 2 (CCAT2), a type of lncRNA, was initially identified as an oncogene in colon cancer and subsequently identified as a prognostic biomarker in different cancers, including hepatocellular carcinoma, esophageal squamous cell carcinoma, ovarian cancer, lung cancer, breast cancer, and other tumors. Cumulative studies have revealed that the overexpression of CCAT2 is significantly correlated with tumor size, tumor node metastasis (TNM stage), tumor progression, and poor clinical outcomes. The significant role of CCAT2 in various gastrointestinal (GI) malignancies has drawn increased attention in recent years. In the present study, we reviewed recent literature concerning lncRNA CCAT2's role in the development and progression of different GI cancers, including colorectal, gastric, hepatocellular, and oropharyngeal cancer, its interaction with cancer-related molecular mechanisms, and evaluate its potential as a diagnostic and prognostic biomarker in GI patients. In addition, this study shows that CCAT2 can be applied as a novel target for treatment strategies in gastrointestinal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.